×
Evaluation of current medical approaches for COVID-19: a systematic review and meta-ana...
https://doi.org/10.1136/bmjspcare-2020-002554
BMJ Supportive & Palliative Care; Wang M, Wu T et. al.

Sep 22nd, 2020 - Because of the lack of vaccination, it is urgent to find effective antiviral agents for COVID-19 treatment. Online databases were searched for articles published before or on 22 June 2020. Studies reporting the effectiveness and safety of antiviral agents for COVID-19 were analysed. A total of 42 studies were included in this analysis. Hydroxychloroquine (HCQ) was not associated with the incide...

Protocol for the DisCoVeRy trial: multicentre, adaptive, randomised trial of the safety...
https://doi.org/10.1136/bmjopen-2020-041437
BMJ Open; Ader F,

Sep 22nd, 2020 - To find effective and safe treatments for COVID-19, the WHO recommended to systemically evaluate experimental therapeutics in collaborative randomised clinical trials. As COVID-19 was spreading in Europe, the French national institute for Health and Medical Research (Inserm) established a transdisciplinary team to develop a multi-arm randomised controlled trial named DisCoVeRy. The objective of...

Interventions for treatment of COVID-19: A living systematic review with meta-analyses ...
https://doi.org/10.1371/journal.pmed.1003293
PLoS Medicine; Juul S, Nielsen EE et. al.

Sep 17th, 2020 - Coronavirus disease 2019 (COVID-19) is a rapidly spreading disease that has caused extensive burden to individuals, families, countries, and the world. Effective treatments of COVID-19 are urgently needed. This is the first edition of a living systematic review of randomized clinical trials comparing the effects of all treatment interventions for participants in all age groups with COVID-19. We...

The effect of antivirals on COVID-19: a systematic review.
https://doi.org/10.1080/14787210.2021.1823832
Expert Review of Anti-infective Therapy; Hussain N, Yoganathan A et. al.

Sep 14th, 2020 - Coronavirus Disease 2019 is a contagious infection which has infected millions worldwide. The objective of this systematic review is to identify studies pertaining to antivirals, both as sole and combined therapies, in COVID-19 patients and review the clinical outcomes of these treatment methods. A systematic review was conducted using Preferred Reporting Items or Systematic Reviews and Meta-an...

A Systematic Review of Multisystem Inflammatory Syndrome in Children Associated With SA...
https://doi.org/10.1097/INF.0000000000002888
The Pediatric Infectious Disease Journal; Kaushik A, Gupta S et. al.

Sep 14th, 2020 - Recently, severe manifestations associated with coronavirus disease 2019 (COVID-19) called multisystem inflammatory syndrome in children (MIS-C) have been recognized. Analysis of studies for this novel syndrome is needed for a better understanding of effective management among affected children. An extensive search strategy was conducted by combining the terms multisystem inflammatory syndrome ...

COVID-19 associated complications and potential therapeutic targets.
https://doi.org/10.1016/j.ejphar.2020.173548
European Journal of Pharmacology; Monpara JD, Sodha SJ et. al.

Sep 14th, 2020 - The global pandemic COVID-19, caused by novel coronavirus SARS-CoV-2, has emerged as severe public health issue crippling world health care systems. Substantial knowledge has been generated about the pathophysiology of the disease and possible treatment modalities in a relatively short span of time. As of August 19, 2020, there is no approved drug for the treatment of COVID-19. More than 600 cl...

Multicenter interim guidance on use of antivirals for children with COVID-19/SARS-CoV-2.
https://doi.org/10.1093/jpids/piaa115
Journal of the Pediatric Infectious Diseases Society; Chiotos K, Hayes M et. al.

Sep 12th, 2020 - Although Coronavirus Disease 2019 (COVID-19) is a mild infection in most children, a small proportion develop severe or critical illness. Data evaluating agents with potential antiviral activity continue to expand, such that updated guidance is needed regarding use of these agents in children. A panel of pediatric infectious diseases physicians and pharmacists from 20 geographically diverse Nor...

Covid-19: US should end Gilead's monopoly on producing remdesivir, report says.
https://doi.org/10.1136/bmj.m3537
BMJ (Clinical Research Ed.); Tanne JH

Sep 11th, 2020 - Covid-19: US should end Gilead's monopoly on producing remdesivir, report says.|2020|Tanne JH,|

COVID-19 convalescent plasma clears SARS-CoV-2 refractory to remdesivir in an infant wi...
https://doi.org/10.1182/bloodadvances.2020002507
Blood Advances; Rodriguez Z, Shane AL et. al.

Sep 11th, 2020 - COVID-19 convalescent plasma clears SARS-CoV-2 refractory to remdesivir in an infant with congenital heart disease.|2020|Rodriguez Z,Shane AL,Verkerke H,Lough C,Zimmerman MG,|

Remdesivir emergency approvals: a comparison of the US, Japanese and EU systems.
https://doi.org/10.1080/17512433.2020.1821650
Expert Review of Clinical Pharmacology; Saint-Raymond A, Sato J et. al.

Sep 10th, 2020 - there were no formal regulatory approvals for antivirals for the COVID-19 pandemic as of June 2020. We compare the first regulatory approvals for remdesivir, through emergency pathways available to three of the main regulators in the world, the US, Japan and the EU. We look at the data supporting the decisions and how authorities exchanged information and collaborated to speed up approvals. Bas...

Remdesivir, a remedy or a ripple in severe COVID-19?
https://doi.org/10.1080/13543784.2020.1821645
Expert Opinion on Investigational Drugs; Doggrell SA

Sep 8th, 2020 - In clinical trial for the Ebola virus, the broad-spectrum anti-viral agent remdesivir was shown to have a good safety profile. Remdesivir is now being tested in severe COVID-19. The Gilead Sciences SIMPLE trial suggests that the short-term use of remdesivir probably does not increase mortality dramatically or have serious short-term toxicity when used to treat severe COVID-19. The Adaptive COVI...

Chemoprophylaxis, diagnosis, treatments, and discharge management of COVID-19: An evide...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7472403
Military Medical Research; Jin YH, Zhan QY et. al.

Sep 5th, 2020 - The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of a rapidly spreading illness, coronavirus disease 2019 (COVID-19), affecting more than seventeen million people around the world. Diagnosis and treatment guidelines for clinicians caring for patients are needed. In the early stage, we have issued "A rapid advice guideline for the diagnosis and treatment of 201...

Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7474075
Nature Communications; Fu L, Ye F et. al.

Sep 5th, 2020 - COVID-19 was declared a pandemic on March 11 by WHO, due to its great threat to global public health. The coronavirus main protease (Mpro, also called 3CLpro) is essential for processing and maturation of the viral polyprotein, therefore recognized as an attractive drug target. Here we show that a clinically approved anti-HCV drug, Boceprevir, and a pre-clinical inhibitor against feline infecti...

Future perspective: biologic agents in patients with severe COVID-19.
https://doi.org/10.1080/08923973.2020.1818770
Immunopharmacology and Immunotoxicology; Yalcin AD, Yalcin AN

Sep 4th, 2020 - The SARS-CoV-2 is a β-CoV, which is enveloped by non-segmented positive-stranded RNA virüs. When β-CoV infects the respiratory tract, it can cause mild and/or severe acute respiratory syndrome (SARS) with consequent release of cytokines/mediators, including interleukin (IL)-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8 (CXCL8), IL-10, IP10, IL-12, IL-13, IL-17, IL-33, IL-25, IL-37, IL-38, GCSF, GM-CSF...

COVID-19 in lung transplant recipients: A single center case series from New York City.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7436464
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons; Aversa M, Benvenuto L et. al.

Sep 3rd, 2020 - There are limited data describing COVID-19 in lung transplant recipients. We performed a single center, retrospective case series study of lung transplant patients followed by the Columbia Lung Transplant program who tested positive for SARS-CoV-2 between March 19-May 19, 2020. 32 lung transplant patients developed mild (16%), moderate (44%), or severe (41%) COVID-19. The median age of patients...

Quantifying the effect of remdesivir in rhesus macaques infected with SARS-CoV-2.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7443325
Virology Dobrovolny HM

Sep 3rd, 2020 - The world is in the midst of a pandemic caused by a novel coronavirus and is desperately searching for possible treatments. The antiviral remdesivir has shown some effectiveness against SARS-CoV-2 in vitro and in a recent animal study. We use data from a study of remdesivir in rhesus macaques to fit a viral kinetics model in an effort to determine the most appropriate mathematical descripton of...

Doxycycline treatment of high-risk COVID-19-positive patients with comorbid pulmonary d...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7476338
Therapeutic Advances in Respiratory Disease; Yates PA, Newman SA et. al.

Sep 2nd, 2020 - Infection with novel SARS-CoV-2 carries significant morbidity and mortality in patients with pulmonary compromise, such as lung cancer, autoimmune disease, and pneumonia. For early stages of mild to moderate disease, care is entirely supportive.Antiviral drugs such as remdesivir may be of some benefit but are reserved for severe cases given limited availability and potential toxicity. Repurposi...

Remdesivir: First Approval.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7459246
Drugs Lamb YN

Sep 1st, 2020 - The antiviral agent remdesivir (Veklury®; Gilead Sciences), nucleotide analogue prodrug, has broad-spectrum activity against viruses from several families. Having demonstrated potent antiviral activity against coronaviruses in preclinical studies, remdesivir emerged as a candidate drug for the treatment of the novel coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrom...

Remdesivir - remdesivir injection-Gilead Sciences, Inc.
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=98b7e6bf-2668-4a61-a874-194eb674b15c

Aug 31st, 2020 - SPL UNCLASSIFIED SECTION The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) to permit the emergency use of the unapproved product Veklury (remdesivir) for treatment of suspected or laboratory confirmed coronavirus disease 2019 (COVID-19) in hospitalized adult and pediatric patients. BOXED WARNING SECTION Health care providers must submit a report on al...

Data Monitoring for the Chinese Clinical Trials of Remdesivir in Treating Patients with...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7229886
Therapeutic Innovation & Regulatory Science; Shih WJ, Yao C et. al.

Aug 31st, 2020 - Two phase-III, double-blind, randomized clinical trials of remdesivir plus SOC (standard of care) versus placebo plus SOC have been conducted in Wuhan hospitals by Chinese investigators during the urgent COVID-19 epidemic [ClincalTrials.gov NCT04257656 and NCT04252664]. These trials have been highly anticipated worldwide. We expect investigators of the trials will soon report the clinical and l...